Newborn Screening for Vitamin B6 Non-responsive Classical Homocystinuria: Systematical Evaluation of a Two-Tier

Jürgen G Okun1, Hongying Gan-Schreier2, Tawfeq Ben-Omran3

  • 1Department of General Pediatrics, Division of Inherited Metabolic Diseases, University Children's Hospital, Heidelberg, Germany. juergen.okun@med.uni-heidelberg.de.

JIMD Reports
|June 22, 2016
PubMed

Insights

Early detection of classical homocystinuria (HCU) is crucial. A new two-tier newborn screening strategy using methionine to phenylalanine ratio and homocysteine levels demonstrates 100% accuracy in identifying HCU cases.

Area of Science:

  • Biochemistry
  • Genetics
  • Public Health

Background:

  • Classical homocystinuria (HCU) is a genetic disorder treatable with early intervention.
  • Existing newborn screening methods require optimization for HCU detection.

Purpose of the Study:

  • To develop and validate a cost-effective two-tier strategy for newborn screening of HCU.
  • To improve the efficiency and accuracy of HCU detection in neonates.

Main Methods:

  • Reevaluation of a large newborn screening dataset (125,047 neonates) from Qatar.
  • Analysis included homocysteine (Hcy), methionine (Met), and Met to phenylalanine (Phe) ratio.
  • Cross-validation with international newborn screening programs.

Main Results:

  • The Met to Phe ratio effectively screened out approximately 90% of normal samples in the first tier.
  • Only 10% of samples required a second-tier Hcy measurement.
  • The strategy achieved 100% sensitivity and specificity in HCU screening.

Conclusions:

  • A two-tier algorithm utilizing Met to Phe ratio followed by Hcy measurement is highly effective for HCU newborn screening.
  • This optimized strategy enhances diagnostic accuracy while reducing laboratory workload.
  • The findings support the implementation of this improved screening protocol globally.
Abstract

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
57
Pedigree Analysis01:35

Pedigree Analysis

Overview
90.5K
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
990
Automated Microbial Diagnostics01:24

Automated Microbial Diagnostics

Automated diagnostic analyzers have transformed clinical microbiology by providing rapid and reliable methods for pathogen identification and antibiotic susceptibility testing. Among these systems, the Vitek 2 is widely used because it automates the traditionally labor-intensive processes of microbial identification (ID) and antibiotic susceptibility testing (AST), delivering standardized and timely results that are essential for effective patient care.Microbial Identification with ID CardsThe...
3
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
313